| Zacks Company Profile for Syros Pharmaceuticals, Inc. (SYRS : NSDQ) |
|
|
| |
| • Company Description |
| Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Number of Employees: 118 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $3.70 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 87,956 shares |
| Shares Outstanding: 20.60 (millions) |
| Market Capitalization: $76.20 (millions) |
| Beta: 1.67 |
| 52 Week High: $11.50 |
| 52 Week Low: $2.42 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
18.59% |
14.10% |
| 12 Week |
2.49% |
-4.86% |
| Year To Date |
3.06% |
-6.25% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
35 Cambridge Park Drive 4th Floor
-
CAMBRIDGE,MA 02140
USA |
ph: 617-744-1340
fax: - |
khunady@syros.com |
http://www.syros.com |
|
|
| |
| • General Corporate Information |
Officers
Nancy Simonian - President; Chief Executive Officer and Director
Peter Wirth - Chairman
Jason Haas - Chief Financial Officer
Srinivas Akkaraju - Director
Mark J. Alles - Director
|
|
Peer Information
Syros Pharmaceuticals, Inc. (CORR.)
Syros Pharmaceuticals, Inc. (RSPI)
Syros Pharmaceuticals, Inc. (CGXP)
Syros Pharmaceuticals, Inc. (BGEN)
Syros Pharmaceuticals, Inc. (GTBP)
Syros Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87184Q206
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/08/23
|
|
Share - Related Items
Shares Outstanding: 20.60
Most Recent Split Date: 9.00 (0.10:1)
Beta: 1.67
Market Capitalization: $76.20 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-1.10 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-4.18 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/08/23 |
|
|
|
| |
